Stem definition | Drug id | CAS RN |
---|---|---|
sulpiride derivatives | 179 | 71675-85-9 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
7.50 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 46.40 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 48 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 26, 2020 | FDA | ACACIA PHARMA LTD | |
Jan. 1, 1986 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Extrapyramidal disorder | 233.17 | 24.18 | 82 | 7680 | 12320 | 53328984 |
Schizophrenia | 174.40 | 24.18 | 63 | 7699 | 10216 | 53331088 |
Hyperprolactinaemia | 150.68 | 24.18 | 43 | 7719 | 3272 | 53338032 |
Sopor | 146.05 | 24.18 | 68 | 7694 | 21016 | 53320288 |
Drug abuse | 138.06 | 24.18 | 97 | 7665 | 65429 | 53275875 |
Blood prolactin increased | 125.00 | 24.18 | 37 | 7725 | 3202 | 53338102 |
Electrocardiogram QT prolonged | 103.91 | 24.18 | 77 | 7685 | 56326 | 53284978 |
Neuroleptic malignant syndrome | 102.97 | 24.18 | 45 | 7717 | 11988 | 53329316 |
Galactorrhoea | 96.91 | 24.18 | 32 | 7730 | 3963 | 53337341 |
Akathisia | 96.61 | 24.18 | 39 | 7723 | 8532 | 53332772 |
Metabolic syndrome | 90.13 | 24.18 | 24 | 7738 | 1410 | 53339894 |
Psychotic disorder | 88.63 | 24.18 | 51 | 7711 | 24334 | 53316970 |
Antipsychotic drug level increased | 82.01 | 24.18 | 27 | 7735 | 3312 | 53337992 |
Hallucination, auditory | 78.48 | 24.18 | 37 | 7725 | 11736 | 53329568 |
Parkinsonism | 74.82 | 24.18 | 33 | 7729 | 8980 | 53332324 |
Mental impairment | 71.23 | 24.18 | 36 | 7726 | 13273 | 53328031 |
Drug interaction | 68.70 | 24.18 | 118 | 7644 | 219211 | 53122093 |
Myocarditis | 67.06 | 24.18 | 30 | 7732 | 8438 | 53332866 |
Sedation | 64.90 | 24.18 | 45 | 7717 | 29630 | 53311674 |
Differential white blood cell count abnormal | 64.15 | 24.18 | 16 | 7746 | 724 | 53340580 |
Confusional state | 62.79 | 24.18 | 106 | 7656 | 194115 | 53147189 |
Aggression | 54.75 | 24.18 | 37 | 7725 | 23366 | 53317938 |
Mydriasis | 53.01 | 24.18 | 28 | 7734 | 11298 | 53330006 |
Pain | 52.40 | 24.18 | 11 | 7751 | 588387 | 52752917 |
Dystonia | 52.06 | 24.18 | 29 | 7733 | 12992 | 53328312 |
Suicide attempt | 50.99 | 24.18 | 52 | 7710 | 58116 | 53283188 |
Tremor | 50.75 | 24.18 | 76 | 7686 | 125660 | 53215644 |
Tardive dyskinesia | 49.63 | 24.18 | 24 | 7738 | 8046 | 53333258 |
Delusion | 48.71 | 24.18 | 27 | 7735 | 11982 | 53329322 |
Neutrophil count increased | 47.70 | 24.18 | 29 | 7733 | 15281 | 53326023 |
Salivary hypersecretion | 46.82 | 24.18 | 22 | 7740 | 6921 | 53334383 |
Overdose | 46.17 | 24.18 | 67 | 7695 | 107669 | 53233635 |
CSF measles antibody positive | 45.94 | 24.18 | 8 | 7754 | 57 | 53341247 |
Rubella antibody positive | 45.12 | 24.18 | 8 | 7754 | 64 | 53341240 |
Hallucination | 43.36 | 24.18 | 46 | 7716 | 53792 | 53287512 |
Intentional self-injury | 43.14 | 24.18 | 33 | 7729 | 25251 | 53316053 |
Neutropenia | 42.54 | 24.18 | 80 | 7682 | 159105 | 53182199 |
Blood brain barrier defect | 42.03 | 24.18 | 8 | 7754 | 98 | 53341206 |
Mental disorder | 41.99 | 24.18 | 32 | 7730 | 24344 | 53316960 |
White blood cell count increased | 41.73 | 24.18 | 42 | 7720 | 46203 | 53295101 |
Catatonia | 40.80 | 24.18 | 17 | 7745 | 4023 | 53337281 |
Treatment noncompliance | 37.38 | 24.18 | 34 | 7728 | 33001 | 53308303 |
Thunderclap headache | 37.25 | 24.18 | 8 | 7754 | 185 | 53341119 |
Antipsychotic drug level decreased | 36.69 | 24.18 | 8 | 7754 | 199 | 53341105 |
Accommodation disorder | 36.52 | 24.18 | 9 | 7753 | 387 | 53340917 |
Organic brain syndrome | 35.92 | 24.18 | 8 | 7754 | 220 | 53341084 |
Grandiosity | 35.82 | 24.18 | 8 | 7754 | 223 | 53341081 |
Euphoric mood | 35.71 | 24.18 | 16 | 7746 | 4513 | 53336791 |
CSF protein increased | 34.07 | 24.18 | 9 | 7753 | 512 | 53340792 |
Loss of consciousness | 33.77 | 24.18 | 60 | 7702 | 114152 | 53227152 |
Leukopenia | 33.38 | 24.18 | 47 | 7715 | 73416 | 53267888 |
Coma | 33.37 | 24.18 | 43 | 7719 | 61740 | 53279564 |
Negative thoughts | 33.18 | 24.18 | 10 | 7752 | 919 | 53340385 |
Ventricular dyskinesia | 32.80 | 24.18 | 7 | 7755 | 157 | 53341147 |
Type 2 diabetes mellitus | 32.75 | 24.18 | 31 | 7731 | 31639 | 53309665 |
Bladder trabeculation | 32.73 | 24.18 | 6 | 7756 | 59 | 53341245 |
Amenorrhoea | 32.48 | 24.18 | 19 | 7743 | 9330 | 53331974 |
Blood folate decreased | 32.44 | 24.18 | 9 | 7753 | 617 | 53340687 |
Antipsychotic drug level above therapeutic | 32.11 | 24.18 | 10 | 7752 | 1026 | 53340278 |
Agitation | 31.97 | 24.18 | 41 | 7721 | 58585 | 53282719 |
Binge eating | 30.75 | 24.18 | 8 | 7754 | 429 | 53340875 |
Cerebral artery stenosis | 30.46 | 24.18 | 8 | 7754 | 445 | 53340859 |
Arthralgia | 30.44 | 24.18 | 13 | 7749 | 439770 | 52901534 |
Rash | 29.61 | 24.18 | 14 | 7748 | 446177 | 52895127 |
Serotonin syndrome | 29.52 | 24.18 | 27 | 7735 | 26379 | 53314925 |
Pruritus | 29.37 | 24.18 | 4 | 7758 | 293828 | 53047476 |
Intentional overdose | 29.06 | 24.18 | 42 | 7720 | 67163 | 53274141 |
Waxy flexibility | 28.77 | 24.18 | 6 | 7756 | 120 | 53341184 |
Morose | 28.66 | 24.18 | 5 | 7757 | 36 | 53341268 |
Hemianopia | 28.60 | 24.18 | 9 | 7753 | 955 | 53340349 |
Pain in extremity | 28.21 | 24.18 | 4 | 7758 | 285046 | 53056258 |
Pleocytosis | 28.17 | 24.18 | 8 | 7754 | 597 | 53340707 |
Muscle rigidity | 27.42 | 24.18 | 18 | 7744 | 10823 | 53330481 |
Vertigo | 27.15 | 24.18 | 37 | 7725 | 56044 | 53285260 |
Weight increased | 27.06 | 24.18 | 78 | 7684 | 204489 | 53136815 |
Electrocardiogram T wave abnormal | 26.98 | 24.18 | 11 | 7751 | 2465 | 53338839 |
Cor pulmonale acute | 26.86 | 24.18 | 7 | 7755 | 378 | 53340926 |
Hypochromic anaemia | 26.22 | 24.18 | 10 | 7752 | 1879 | 53339425 |
Cardiogenic shock | 25.90 | 24.18 | 21 | 7741 | 17461 | 53323843 |
Psychiatric decompensation | 25.55 | 24.18 | 9 | 7753 | 1353 | 53339951 |
Toxicity to various agents | 25.53 | 24.18 | 80 | 7682 | 219518 | 53121786 |
Cognitive disorder | 25.49 | 24.18 | 32 | 7730 | 44746 | 53296558 |
Hallucination, olfactory | 24.84 | 24.18 | 6 | 7756 | 237 | 53341067 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Schizophrenia | 371.85 | 23.69 | 134 | 10179 | 9850 | 32493363 |
Antipsychotic drug level below therapeutic | 318.90 | 23.69 | 82 | 10231 | 1887 | 32501326 |
Akathisia | 252.91 | 23.69 | 92 | 10221 | 6933 | 32496280 |
Disinhibition | 225.68 | 23.69 | 67 | 10246 | 2653 | 32500560 |
Obsessive-compulsive disorder | 217.05 | 23.69 | 75 | 10238 | 4859 | 32498354 |
Therapeutic product effect variable | 215.51 | 23.69 | 61 | 10252 | 2035 | 32501178 |
Neuroleptic malignant syndrome | 189.35 | 23.69 | 98 | 10215 | 17397 | 32485816 |
Euphoric mood | 186.42 | 23.69 | 68 | 10245 | 5159 | 32498054 |
Increased appetite | 172.24 | 23.69 | 68 | 10245 | 6408 | 32496805 |
Neutrophil count increased | 167.89 | 23.69 | 88 | 10225 | 16026 | 32487187 |
Psychotic disorder | 156.42 | 23.69 | 95 | 10218 | 22925 | 32480288 |
Electrocardiogram QT prolonged | 154.84 | 23.69 | 116 | 10197 | 39525 | 32463688 |
Antipsychotic drug level increased | 148.60 | 23.69 | 52 | 10261 | 3494 | 32499719 |
Extrapyramidal disorder | 138.43 | 23.69 | 70 | 10243 | 11825 | 32491388 |
Salivary hypersecretion | 135.03 | 23.69 | 61 | 10252 | 8027 | 32495186 |
Suicide attempt | 127.71 | 23.69 | 102 | 10211 | 38142 | 32465071 |
Blood prolactin increased | 126.46 | 23.69 | 38 | 10275 | 1567 | 32501646 |
White blood cell count increased | 120.61 | 23.69 | 102 | 10211 | 41300 | 32461913 |
Mental impairment | 116.73 | 23.69 | 59 | 10254 | 9953 | 32493260 |
Blood creatine phosphokinase increased | 104.54 | 23.69 | 98 | 10215 | 45378 | 32457835 |
Obesity | 104.28 | 23.69 | 55 | 10258 | 10127 | 32493086 |
Leukopenia | 102.23 | 23.69 | 110 | 10203 | 60012 | 32443201 |
Weight increased | 95.73 | 23.69 | 125 | 10188 | 83538 | 32419675 |
Antipsychotic drug level decreased | 95.34 | 23.69 | 27 | 10286 | 901 | 32502312 |
Antipsychotic drug level above therapeutic | 93.56 | 23.69 | 28 | 10285 | 1138 | 32502075 |
Delusion | 88.74 | 23.69 | 54 | 10259 | 13054 | 32490159 |
Hallucination, auditory | 81.46 | 23.69 | 47 | 10266 | 10303 | 32492910 |
Dyslipidaemia | 78.58 | 23.69 | 40 | 10273 | 6843 | 32496370 |
Therapeutic product effect incomplete | 70.85 | 23.69 | 76 | 10237 | 41265 | 32461948 |
Aggression | 68.53 | 23.69 | 73 | 10240 | 39316 | 32463897 |
Tachycardia | 67.86 | 23.69 | 103 | 10210 | 78985 | 32424228 |
Prescribed overdose | 61.32 | 23.69 | 38 | 10275 | 9481 | 32493732 |
Hyperprolactinaemia | 57.79 | 23.69 | 20 | 10293 | 1298 | 32501915 |
Dystonia | 57.50 | 23.69 | 38 | 10275 | 10585 | 32492628 |
Sedation | 56.68 | 23.69 | 47 | 10266 | 18479 | 32484734 |
Leukaemia | 53.91 | 23.69 | 26 | 10287 | 3960 | 32499253 |
Neutropenia | 52.02 | 23.69 | 129 | 10184 | 142046 | 32361167 |
Nausea | 49.56 | 23.69 | 20 | 10293 | 320829 | 32182384 |
Agitation | 46.88 | 23.69 | 73 | 10240 | 57163 | 32446050 |
Diarrhoea | 44.23 | 23.69 | 31 | 10282 | 364771 | 32138442 |
Breast engorgement | 43.61 | 23.69 | 7 | 10306 | 9 | 32503204 |
Lower respiratory tract infection | 43.59 | 23.69 | 50 | 10263 | 29193 | 32474020 |
White blood cell count decreased | 43.57 | 23.69 | 92 | 10221 | 91106 | 32412107 |
Neutrophil count decreased | 42.68 | 23.69 | 63 | 10250 | 47076 | 32456137 |
Drug interaction | 39.55 | 23.69 | 155 | 10158 | 218030 | 32285183 |
Schizoaffective disorder | 39.24 | 23.69 | 15 | 10298 | 1293 | 32501920 |
Psychotic symptom | 37.55 | 23.69 | 15 | 10298 | 1454 | 32501759 |
Parkinsonism | 37.45 | 23.69 | 26 | 10287 | 7843 | 32495370 |
Persecutory delusion | 36.99 | 23.69 | 17 | 10296 | 2322 | 32500891 |
Sopor | 36.33 | 23.69 | 30 | 10283 | 11719 | 32491494 |
Pleurothotonus | 34.61 | 23.69 | 13 | 10300 | 1068 | 32502145 |
Suicidal ideation | 34.61 | 23.69 | 51 | 10262 | 38032 | 32465181 |
Blepharospasm | 34.30 | 23.69 | 13 | 10300 | 1095 | 32502118 |
Paranoia | 34.28 | 23.69 | 28 | 10285 | 10771 | 32492442 |
Hypoventilation | 34.04 | 23.69 | 18 | 10295 | 3326 | 32499887 |
Conduction disorder | 33.16 | 23.69 | 15 | 10298 | 1975 | 32501238 |
Thinking abnormal | 32.55 | 23.69 | 21 | 10292 | 5614 | 32497599 |
Somnolence | 31.59 | 23.69 | 88 | 10225 | 103709 | 32399504 |
Drug ineffective | 31.29 | 23.69 | 218 | 10095 | 383259 | 32119954 |
Disturbance in attention | 31.07 | 23.69 | 38 | 10275 | 23715 | 32479498 |
Arthralgia | 30.96 | 23.69 | 5 | 10308 | 148443 | 32354770 |
Left ventricular dysfunction | 30.49 | 23.69 | 25 | 10288 | 9670 | 32493543 |
Platelet count increased | 29.51 | 23.69 | 24 | 10289 | 9177 | 32494036 |
Drug level increased | 29.35 | 23.69 | 34 | 10279 | 20046 | 32483167 |
Abnormal behaviour | 29.34 | 23.69 | 39 | 10274 | 26427 | 32476786 |
Subacute endocarditis | 28.64 | 23.69 | 6 | 10307 | 53 | 32503160 |
Diffuse large B-cell lymphoma stage II | 28.54 | 23.69 | 6 | 10307 | 54 | 32503159 |
Pain | 28.39 | 23.69 | 12 | 10301 | 187544 | 32315669 |
Treatment noncompliance | 27.01 | 23.69 | 38 | 10275 | 27164 | 32476049 |
Overdose | 26.65 | 23.69 | 74 | 10239 | 87003 | 32416210 |
Myocarditis | 26.62 | 23.69 | 25 | 10288 | 11565 | 32491648 |
Intentional self-injury | 26.36 | 23.69 | 27 | 10286 | 13873 | 32489340 |
Toxicity to various agents | 26.36 | 23.69 | 119 | 10194 | 177922 | 32325291 |
Eosinophil count decreased | 25.68 | 23.69 | 11 | 10302 | 1272 | 32501941 |
Sarcoma metastatic | 25.49 | 23.69 | 6 | 10307 | 94 | 32503119 |
Pain in extremity | 24.80 | 23.69 | 4 | 10309 | 118897 | 32384316 |
Hangover | 23.92 | 23.69 | 10 | 10303 | 1089 | 32502124 |
Impaired self-care | 23.78 | 23.69 | 10 | 10303 | 1105 | 32502108 |
Source | Code | Description |
---|---|---|
ATC | N05AL05 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Benzamides |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D018687 | Antidepressive Agents, Second-Generation |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
FDA MoA | N0000175799 | Dopamine D2 Antagonists |
FDA EPC | N0000175800 | Dopamine-2 Receptor Antagonist |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:65191 | atypical antipsychotics |
CHEBI has role | CHEBI:78298 | environmental contaminants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Postoperative nausea and vomiting | indication | 1488000 | |
Chronic schizophrenia | indication | 83746006 | |
Dysthymia | off-label use | 78667006 | DOID:12139 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.78 | acidic |
pKa2 | 9.09 | Basic |
pKa3 | 0.54 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9084765 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9084765 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9545426 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9545426 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9889118 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | 9889118 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9084765 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9084765 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9545426 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9545426 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9889118 | March 10, 2031 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | 9889118 | March 10, 2031 | TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
10MG/4ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Sept. 1, 2020 | RX | SOLUTION | INTRAVENOUS | Feb. 26, 2025 | NEW CHEMICAL ENTITY |
5MG/2ML (2.5MG/ML) | BARHEMSYS | ACACIA | N209510 | Feb. 26, 2020 | RX | SOLUTION | INTRAVENOUS | Feb. 26, 2025 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.55 | WOMBAT-PK | SCIENTIFIC LITERATURE | |||
D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.50 | WOMBAT-PK | SCIENTIFIC LITERATURE | |||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.89 | PDSP | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.38 | PDSP | |||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.94 | PDSP | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.76 | PDSP | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.95 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 5.81 | PDSP | |||||
D(4) dopamine receptor | GPCR | Ki | 5.63 | PDSP | |||||
5-hydroxytryptamine receptor 1D | GPCR | Ki | 5.87 | PDSP | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.08 | PDSP | |||||
D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.40 | IUPHAR |
ID | Source |
---|---|
D07310 | KEGG_DRUG |
2284233 | RXNORM |
C0103045 | UMLSCUI |
CHEBI:64045 | CHEBI |
CHEMBL243712 | ChEMBL_ID |
DB06288 | DRUGBANK_ID |
D000077582 | MESH_DESCRIPTOR_UI |
2159 | PUBCHEM_CID |
963 | IUPHAR_LIGAND_ID |
4960 | INN_ID |
8110R61I4U | UNII |
17788 | MMSL |
331491 | MMSL |
d04990 | MMSL |
005229 | NDDF |
321636003 | SNOMEDCT_US |
391761004 | SNOMEDCT_US |
4039609 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Barhemsys | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71390-125 | INJECTION, SOLUTION | 2.50 mg | INTRAVENOUS | NDA | 30 sections |